乳腺癌患者多西他赛相关不良反应的表现及管理
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
作者信息
Ho Maria Y, Mackey John R
机构信息
Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
出版信息
Cancer Manag Res. 2014 May 27;6:253-9. doi: 10.2147/CMAR.S40601. eCollection 2014.
Abstract
The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.
摘要
紫杉烷类化疗药物多西他赛已被用于辅助、新辅助和转移性乳腺癌的治疗。尽管大多数患者对多西他赛耐受性良好，但多西他赛的毒性可能会限制给药剂量。不良事件包括输注反应、发热性中性粒细胞减少、疲劳、液体潴留、肺炎、皮肤和指甲毒性、流泪和泪道狭窄、胃肠道并发症以及神经病变。在本综述中，我们探讨了这些并发症以及如何有效管理它们，以改善多西他赛治疗期间及之后患者的生活质量。
相似文献
1
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.乳腺癌患者多西他赛相关不良反应的表现及管理
Cancer Manag Res. 2014 May 27;6:253-9. doi: 10.2147/CMAR.S40601. eCollection 2014.
2
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
3
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.多西他赛在乳腺癌治疗中应用的获益风险评估及更新
Cancer Manag Res. 2013 Oct 14;5:357-65. doi: 10.2147/CMAR.S49321.
4
Docetaxel-associated epiphora.多西他赛相关的泪溢。
Pharmacotherapy. 2006 Jun;26(6):853-67. doi: 10.1592/phco.26.6.853.
5
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.奥布利默森联合多西他赛、阿霉素和环磷酰胺作为原发性乳腺癌的新辅助全身治疗：一项多中心I期研究的最终结果
Ann Oncol. 2008 Oct;19(10):1698-705. doi: 10.1093/annonc/mdn280. Epub 2008 May 13.
6
Epiphora in lung cancer patients receiving docetaxel: a case series.接受多西他赛治疗的肺癌患者的泪溢：病例系列
BMC Res Notes. 2014 May 30;7:322. doi: 10.1186/1756-0500-7-322.
7
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.多西他赛单药治疗转移性乳腺癌的临床疗效
Semin Oncol. 1997 Aug;24(4 Suppl 13):S13-11-S13-18.
8
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.利用 [(18)F]-FDG PET 预测曲妥珠单抗和多西他赛新辅助治疗 HER2 阳性乳腺癌患者的反应，以及在 [(18)F]-FDG PET 预测无应答者中添加贝伐珠单抗（AVATAXHER）：一项开放标签、随机 2 期试验。
Lancet Oncol. 2014 Dec;15(13):1493-1502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30.
9
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review.一名接受多西他赛和环磷酰胺辅助治疗的III期乳腺癌患者发生肺炎和肺纤维化：病例报告及文献综述
J Med Case Rep. 2012 Nov 30;6:413. doi: 10.1186/1752-1947-6-413.
10
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.紫杉烷类用于早期乳腺癌的辅助治疗：系统评价与经济学评估
Health Technol Assess. 2007 Oct;11(40):1-144. doi: 10.3310/hta11400.
引用本文的文献
1
An Experimental Rat Model for Simultaneous Induction of Peripheral Neuropathy and Myelotoxicity by Docetaxel Administration: Evaluating the Protective Role of Dimethyl Fumarate.一种通过多西他赛给药同时诱导周围神经病变和骨髓毒性的实验大鼠模型：评估富马酸二甲酯的保护作用。
Int J Mol Sci. 2025 Jun 19;26(12):5859. doi: 10.3390/ijms26125859.
2
Peritoneal Metastasis Mimicking Chemotherapy-Induced Complications in Lung Adenocarcinoma: A Diagnostic Challenge of a Case Report.肺腺癌中酷似化疗诱导并发症的腹膜转移：一例报告的诊断挑战
Cureus. 2025 Apr 18;17(4):e82530. doi: 10.7759/cureus.82530. eCollection 2025 Apr.
3
The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer.组蛋白修饰在调节晚期前列腺癌恩杂鲁胺敏感性中的作用机制。
Int J Biol Sci. 2025 Apr 13;21(6):2880-2890. doi: 10.7150/ijbs.109638. eCollection 2025.
4
Survivorship Considerations and Management in the Adolescent and Young Adult Sarcoma Population: A Review.青少年和青年肉瘤患者的生存考量与管理：综述
Curr Oncol. 2025 Apr 3;32(4):214. doi: 10.3390/curroncol32040214.
5
Identification of phyto-compounds from as inhibitors of 17β-hydroxysteroid dehydrogenase: a computational approach against prostate cancer.从[具体植物名称未给出]中鉴定作为17β-羟基类固醇脱氢酶抑制剂的植物化合物：一种针对前列腺癌的计算方法。
In Silico Pharmacol. 2025 Mar 28;13(1):50. doi: 10.1007/s40203-025-00332-6. eCollection 2025.
6
Unraveling the Crimson puzzle: Two case reports/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer.解开深红色谜团：两例乳腺癌患者在接受多西他赛、卡铂、曲妥珠单抗和帕妥珠单抗联合化疗后发生出血性膀胱炎的病例报告/病例系列
Medicine (Baltimore). 2025 Mar 28;104(13):e41906. doi: 10.1097/MD.0000000000041906.
7
Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines.低剂量萝卜硫素与多西他赛联合作用于前列腺癌细胞系的线粒体功能和代谢重编程
Int J Mol Sci. 2025 Jan 24;26(3):1013. doi: 10.3390/ijms26031013.
8
Role of scaffold proteins in the heterogeneity of glioblastoma.支架蛋白在胶质母细胞瘤异质性中的作用。
Cell Commun Signal. 2024 Oct 7;22(1):477. doi: 10.1186/s12964-024-01809-1.
9
The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.吉西他滨和多西他赛化疗治疗复发和难治性骨肉瘤的疗效：系统评价和临床前研究。
Cancer Med. 2024 Sep;13(18):e70248. doi: 10.1002/cam4.70248.
10
CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.CREB 结合蛋白/P300 溴结构域抑制减少三阴性乳腺癌中的中性粒细胞积累并激活抗肿瘤免疫。
JCI Insight. 2024 Sep 17;9(20):e182621. doi: 10.1172/jci.insight.182621.
本文引用的文献
1
Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.早期乳腺癌接受辅助多西紫杉醇化疗的女性中过度流泪的发生率。
J Clin Oncol. 2013 Jun 10;31(17):2123-7. doi: 10.1200/JCO.2012.45.6574. Epub 2013 May 6.
2
Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important?早期乳腺癌辅助多西他赛治疗相关的溢泪和泪小管狭窄：过度流泪在临床上重要吗？
J Clin Oncol. 2013 Jun 10;31(17):2076-7. doi: 10.1200/JCO.2012.47.5897. Epub 2013 May 6.
3
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.仅在第一个和第二个化疗周期中使用初级粒细胞集落刺激因子预防，或在所有化疗周期中使用初级粒细胞集落刺激因子预防，用于有发热性中性粒细胞减少风险的乳腺癌患者。
J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29.
4
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.辅助多西他赛、多柔比星和环磷酰胺治疗淋巴结阳性乳腺癌：III 期随机 BCIRG 001 试验的 10 年随访结果。
Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.
5
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review.一名接受多西他赛和环磷酰胺辅助治疗的III期乳腺癌患者发生肺炎和肺纤维化：病例报告及文献综述
J Med Case Rep. 2012 Nov 30;6:413. doi: 10.1186/1752-1947-6-413.
6
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.多西他赛序贯治疗对氟尿嘧啶、表柔比星和环磷酰胺标准方案治疗阳性淋巴结乳腺癌的附加获益：UNICANCER-PACS01 试验的 8 年随访结果。
Oncologist. 2012;17(7):900-9. doi: 10.1634/theoncologist.2011-0442. Epub 2012 May 18.
7
Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.多西他赛治疗晚期非小细胞肺癌相关的间质性肺病。
Anticancer Res. 2012 Mar;32(3):1103-6.
8
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.不同化疗方案治疗早期乳腺癌的比较：123 项随机试验 10 万名女性长期结局的荟萃分析。
Lancet. 2012 Feb 4;379(9814):432-44. doi: 10.1016/S0140-6736(11)61625-5. Epub 2011 Dec 5.
9
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
10
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.静脉治疗用于去势抵抗性前列腺癌：毒性和不良反应。
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S15-9. doi: 10.1016/j.urolonc.2011.09.003. Epub 2011 Oct 19.
Zotero 插件